Mediwheel <wellness@mediwheel.in>

Tue 3/5/2024 2:59 PM

To:PHC [MH-Ghaziabad] <phc.ghaziabad@manipalhospitals.com> Cc:customercare@mediwheel.in <customercare@mediwheel.in>



011-41195959

Dear Manipal Hospital

We have received a booking request with the following details. Provide your confirmation by clicking on the Yes button.

You confirm this booking?

Name

: MS. DWIVEDI RITIKA

Contact Details

: 8917007525

Hospital Package Name

Mediwheel Full Body Health Checkup Female Below 40

Appointment Date

: 09-03-2024

	Member Information	
	Member Information	
Booked Member Name		or had a provincial in a second control of the cont
MC DWIVED DITIES	Age	Gender
MO. DWIVEDI RITKA	34 year	Female

Tests included in this Package -

- · Pap Smear
- Stool Test
- Gynae Consultation
- · Thyroid Profile
- ESR
- **Blood Glucose (Fasting)**
- General Physician Consultation
- TMT OR 2D ECHO
- **Blood Group**
- **Blood Glucose (Post Prandial)**
- Chest X-ray
- ECG
- USG Whole Abdomen
- Eye Check-up consultation
- Urine Sugar Fasting
- Urine Sugar PP
- **Dental Consultation**
- Urine analysis
- CBC
- HbA1c
- · Lipid Profile
- Kidney Profile
- · Liver profile

Thanks, Mediwheel Team Please Download Mediwheel App





You have received this mail because your e-mail ID is registered with Arcofemi Healthcare Limited This is a system-generated e-mail please don't reply to this message.



भारत सरकार Government of India



रिविका व्हेंबवेदी Ritika Dwivedi $\frac{3\pi G_{\rm c}^{\rm total}}{4\pi} (M) \approx \frac{1}{4\pi} (M) (M) (M) (M)$



2437 0257 5464 - आम आदमी का अधिकार

Unique Identification Authority of india

STEEL

D/O: एस के द्विवेदी, बी548/250 विकास नगर मानक नगर, सेंट्रन विद्यालय के पीछे, मानकनगर, सद्यनक, मानकाकर, उत्सर प्रदेश, 226011

Address: D/O: S.K. Dwivedi, B546/250, vikram nagar manak nagar. behind central school. Manaknagar, Lucknow, Manaknagar, Ultar Pradesh. 226011

2437 0257 5464



Pelp & local gov.in







Name

MRS RITIKA DWIVEDI

Age

34 Yr(s) Sex :Female

Registration No

: MH011761145

Lab No

202403001106

Patient Episode

H18000001895

Collection Date:

09 Mar 2024 10:26

Referred By

HEALTH CHECK MGD

Reporting Date:

10 Mar 2024 12:51

Receiving Date

: 09 Mar 2024 10:26

BIOCHEMISTRY

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

THYROID PROFILE, Serum

Specimen Type : Serum

T3 - Triiodothyronine (ELFA)
T4 - Thyroxine (ELFA)

0.920 ng/ml 7.990 ug/dl [0.610-1.630] [4.680-9.360]

Thyroid Stimulating Hormone

2.070 µIU/mL

[0.250-5.000]

NOTE:

TSH stimulates the thyroid gland to produce the main thyroid hormones T3 and T4. In cases of hyperthyroidism TSH level is severely inhibited and may even be undetectable. In rare forms of high-origin hyperthyroidism, the TSH level is not reduced, since the negative-feedback control of the thyroid hormones has no effect.

In cases of primary hypothyroidism, TSH levels are always much higher than normal and thyroid hormone levels are low.

The TSH assay aids in diagnosing thyroid or hypophysial disorders.

The T4 assay aids in assessing thyroid function, which is characterized by a decrease in thyroxine levels in patients with hypothyroidism and an increase in patients with hypothyroidism.

The test has been carried out in Fully Automated Immunoassay System VIDAS using ELFA (Enzyme Linked Fluorescence Assay) technology.

Page1 of 2





Name

MRS RITIKA DWIVEDI

Age

34 Yr(s) Sex :Female

Registration No

MH011761145

Lab No

202403001106

Patient Episode

H18000001895

Collection Date:

09 Mar 2024 10:26

Referred By

HEALTH CHECK MGD

Reporting Date:

10 Mar 2024 13:44

Receiving Date

09 Mar 2024 10:26

BLOOD BANK

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Blood Group & Rh Typing (Agglutination by gel/tube technique) Specimen-Blood

Blood Group & Rh typing

A Rh(D) Positive

Technical note:

ABO grouping and Rh typing is done by cell and serum grouping by microplate / gel technique.

Page 2 of 2

NOTE:

- Abnormal Values

-----END OF REPORT-----

Dr. Charu Agarwal **Consultant Pathologist**







Name

: MRS RITIKA DWIVEDI

Registration No

: MH011761145

Patient Episode

: H18000001895

Referred By

: HEALTH CHECK MGD

Receiving Date

: 09 Mar 2024 10:26

Age

34 Yr(s) Sex :Female

Lab No

202403001106

Collection Date:

202403001100

09 Mar 2024 10:26

Reporting Date:

09 Mar 2024 12:22

HAEMATOLOGY

T	EST	

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

COMPLETE BLOOD COUNT (AUTOMATED)	SPECIMEN-EDTA Whole Bl	Lood
RBC COUNT (IMPEDENCE) HEMOGLOBIN Method:cyanide free SLS-colorim	4.70 11.5 # etry	millions/cumm g/dl	[3.80-4.80] [12.0-15.0]
HEMATOCRIT (CALCULATED) MCV (DERIVED) MCH (CALCULATED) MCHC (CALCULATED) RDW CV% (DERIVED) Platelet count Method: Electrical Impedance	37.8 80.4 # 24.5 # 30.4 # 17.2 # 417 #	% fL pg g/dl % x 10 ³ cells/cumm	[36.0-46.0] [83.0-101.0] [25.0-32.0] [31.5-34.5] [11.6-14.0] [150-410]
MPV (DERIVED)	12.1		
WBC COUNT (TC) (IMPEDENCE) DIFFERENTIAL COUNT (VCS TECHNOLOGY/MICROSCOPY)	8.39	\times 10 3 cells/cumm	[4.00-10.00]
Neutrophils Lymphocytes Monocytes Eosinophils Basophils	57.0 36.0 6.0 1.0 0.0	00 00 00 00 00	[40.0-80.0] [20.0-40.0] [2.0-10.0] [1.0-6.0] [0.0-2.0]
ESR	29.0 #	mm/1sthour	[0.0-

Page1 of 7







Name

: MRS RITIKA DWIVEDI

: MH011761145

Registration No Patient Episode

: H18000001895

Referred By

Receiving Date

: HEALTH CHECK MGD : 09 Mar 2024 10:26

Age

34 Yr(s) Sex : Female

Lab No

202403001106

Collection Date:

09 Mar 2024 10:26

Reporting Date:

09 Mar 2024 16:40

BIOCHEMISTRY

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Glycosylated Hemoglobin

Specimen: EDTA

HbA1c (Glycosylated Hemoglobin) Method: HPLC

5.1

00

[0.0-5.6]

As per American Diabetes Association (ADA

HbAlc in %

Non diabetic adults >= 18 years <5.7

Prediabetes (At Risk) 5.7-6.4 Diagnosing Diabetes >= 6.5

Estimated Average Glucose (eAG)

mg/dl

Comments : HbA1c provides an index of average blood glucose levels over the past

8-12 weeks and is a much better indicator of long term glycemic control.

ROUTINE URINE ANALYSIS (Semi Automated) Specimen-Urine

MACROSCOPIC DESCRIPTION

Colour

PALE YELLOW

(Pale Yellow - Yellow)

Appearance Reaction[pH]

CLEAR

6.5

(4.6 - 8.0)

Specific Gravity

1.010

(1.003 - 1.035)

CHEMICAL EXAMINATION

Protein/Albumin

Negative

(NEGATIVE)

Glucose

NIL

(NIL)

Ketone Bodies

Negative

(NEGATIVE)

Urobilinogen

Normal

(NORMAL)

Page 2 of 7







Name

: MRS RITIKA DWIVEDI

: MH011761145

Registration No Patient Episode

: H18000001895

MICROSCOPIC EXAMINATION (Automated/Manual)

Referred By

: HEALTH CHECK MGD

2-4 /hpf

Receiving Date

Pus Cells

: 09 Mar 2024 10:36

Age

34 Yr(s) Sex :Female

Lab No

(0-5/hpf)

202403001106

Collection Date:

09 Mar 2024 10:36

Reporting Date:

09 Mar 2024 12:25

CLINICAL PATHOLOGY

	RBC Epithelial Cells CASTS Crystals Bacteria	NIL 4-6 NIL NIL	/hpf		(0-5/hpf) (0-2/hpf)		
	OTHERS	NIL					
	Serum LIPID PROFILE						
	Serum TOTAL CHOLESTEROL Method:Oxidase, esterase, per	oxide	1	71	mg/dl	[<200] Moderate risk:200-239 High risk:>240	
	TRIGLYCERIDES (GPO/POD)			75	mg/dl	[<150] Borderline high:151-199 High: 200 - 499 Very high:>500	
	HDL- CHOLESTEROL Method: Enzymatic Immunoimh	ibition		55	mg/dl	[35-65]	
	VLDL- CHOLESTEROL (Calculate CHOLESTEROL, LDL, CALCULATED		101	15.0	mg/dl mg/dl	[0-35] [<120.0] Near/	
Al	bove optimal-100-129					Borderline High: 130-159	
	T.Chol/HDL.Chol ratio(Calcu	lated)	3	.1	8	High Risk:160-189 <4.0 Optimal 4.0-5.0 Borderline >6 High Risk	
	LDL.CHOL/HDL.CHOL Ratio(Calc	ulated)	1	. 8		<pre><3 Optimal 3-4 Borderline >6 High Risk</pre>	
					· · · · · · · · · · · · · · · · · · ·		

Page 3 of 7







Name

: MRS RITIKA DWIVEDI

Age

34 Yr(s) Sex : Female

Registration No

: MH011761145

Lab No

202403001106

Patient Episode

: H18000001895

Collection Date:

09 Mar 2024 10:26

Referred By

: HEALTH CHECK MGD

Reporting Date:

09 Mar 2024 11:13

Receiving Date

: 09 Mar 2024 10:26

BIOCHEMISTRY

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Note:

Reference ranges based on ATP III Classifications.

Lipid profile is a panel of blood tests that serves as initial broad medical screening tool for abnormalities in lipids, the results of this tests can identify certain genetic diseases and determine approximate risks for cardiovascular disease, certain forms of pancreatitis and other diseases

KIDNEY PROFILE

Specimen: Serum

L STATE OF THE STA				
UREA	14.9	#	mg/dl	[15.0-40.0]
Method: GLDH, Kinatic assay			-	
BUN, BLOOD UREA NITROGEN	7.0	#	mg/dl	[8.0-20.0]
Method: Calculated				[0.0 20.0]
CREATININE, SERUM	0.67	#	mg/dl	[0.70-1.20]
Method: Jaffe rate-IDMS Standardization		85		[0.70 1.20]
URIC ACID	5.8		mg/dl	[4.0-8.5]
Method:uricase PAP			3,	[1.0 0.5]
SODIUM, SERUM	134.60	#	mmol/L	[136.00-144.00]
				1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1
POTASSIUM, SERUM	4.52	*	mmol/L	[3.60-5.10]
SERUM CHLORIDE	103.1		mmol/L	[101.0-111.0]
Method: ISE Indirect			*	
eGFR (calculated)	115.1		ml/min/1.73sq.m	[>60.01
eGFR (calculated) Technical Note	115.1		ml/min/1.73sq.m	[>60.0]

eGFR which is primarily based on Serum Creatinine is a derivation of CKD-EPI 2009 equation normalized to1.73 sq.m BSA and is not applicable to individuals below 18 years. eGFR tends to be less accurate when Serum Creatinine estimation is indeterminate e.g. patients at extremes of muscle mass, on unusual diets etc. and samples with severe Hemolysis Icterus / Lipemia.

Page 4 of 7







Name

: MRS RITIKA DWIVEDI

Registration No

: MH011761145

Patient Episode

: H18000001895

Referred By

: HEALTH CHECK MGD

Receiving Date

TECT

: 09 Mar 2024 10:26

Age

34 Yr(s) Sex :Female

Lab No

202403001106

Collection Date:

09 Mar 2024 10:26

Reporting Date:

09 Mar 2024 11:14

BIOCHEMISTRY

TEST	RESULT	UNIT	BIOI	LOGICAL REFERENCE INTERVAL
LIVER FUNCTION TEST				
BILIRUBIN - TOTAL Method: D P D	0.40		mg/dl	[0.30-1.20]
BILIRUBIN - DIRECT Method: DPD	0.07		mg/dl	[0.00-0.30]
INDIRECT BILIRUBIN (SERUM) Method: Calculation	0.33		mg/dl	[0.10-0.90]
TOTAL PROTEINS (SERUM) Method: BIURET	7.70		gm/dl	[6.60-8.70]
ALBUMIN (SERUM) Method: BCG	4.49		g/dl	[3.50-5.20]
GLOBULINS (SERUM) Method: Calculation	3.20		gm/dl	[1.80-3.40]
PROTEIN SERUM (A-G) RATIO Method: Calculation	1.40		3	[1.00-2.50]
AST(SGOT) (SERUM) Method: IFCC W/O P5P	42.00 #	ŧ	U/L	[0.00-40.00]
ALT(SGPT) (SERUM) Method: IFCC W/O P5P	37.70		U/L	[14.00-54.00]
Serum Alkaline Phosphatase Method: AMP BUFFER IFCC)	143.0 #	ŧ.	IU/L	[32.0-91.0]
GGT	70.0 #	!	U/L	[7.0-50.0]
				D

Page 5 of 7







Name

: MRS RITIKA DWIVEDI

: MH011761145

Registration No Patient Episode

: H18000001895

Referred By

: HEALTH CHECK MGD

Receiving Date

: 09 Mar 2024 10:26

Age

34 Yr(s) Sex :Female

Lab No

202403001106

Collection Date:

09 Mar 2024 10:26

Reporting Date:

09 Mar 2024 11:14

BIOCHEMISTRY

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Liver function test aids in diagnosis of various pre hepatic, hepatic and post hepatic causes of dysfunction like hemolytic anemia's, viral and alcoholic hepatitis and cholestasis of obstructive causes.

The test encompasses hepatic excretory, synthetic function and also hepatic parenchymal cell damage. LFT helps in evaluating severity, monitoring therapy and assessing prognosis of liver disease and dysfunction.

Page 6 of 7

-----END OF REPORT-----

Dr. Alka Dixit Vats Consultant Pathologist







Name

: MRS RITIKA DWIVEDI

Age

34 Yr(s) Sex :Female

Registration No

: MH011761145

Lab No

202403001109

Patient Episode

: H18000001895

Collection Date:

09 Mar 2024 10:26

Referred By

: HEALTH CHECK MGD

Reporting Date:

09 Mar 2024 13:31

Receiving Date

: 09 Mar 2024 10:26

BIOCHEMISTRY

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

GLUCOSE-Fasting

Specimen: Plasma

GLUCOSE, FASTING (F)

90.0

mg/dl

[70.0-110.0]

Method: Hexokinase

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in Diabetes mellitus, Cushing's syndrome (10-15%), chronic pancreatitis (30%). Drugs corticosteroids, phenytoin, estrogen, thiazides

Decreased in Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortica insufficiency, hypopituitarism, diffuse liver disease, malignancy(adrenocortical, stomach, fibro sarcoma), infant of a diabetic mother enzyme deficiency diseases(e.g.galactosemia),

insulin, ethanol, propranolol, sulfonylureas, tobutamide, and other oral hypoglycemic agents.

Page 7 of 7

-----END OF REPORT-----

Dr. Alka Dixit Vats Consultant Pathologist





NAME	MRS Ritika DWIVEDI	STUDY DATE	09/03/2024 10:55AM
AGE / SEX	34 y / F	HOSPITAL NO.	MH011761145
ACCESSION NO.	R7022734	MODALITY	CR
REPORTED ON	09/03/2024 3:18PM	REFERRED BY	HEALTH CHECK MGD

XR- CHEST PA VIEW

FINDINGS:

LUNGS: Normal. TRACHEA: Normal. CARINA: Normal.

RIGHT AND LEFT MAIN BRONCHI: Normal.

PLEURA: Normal. HEART: Normal.

RIGHT HEART BORDER: Normal. LEFT HEART BORDER:Normal. PULMONARY BAY: Normal. PULMONARY HILA: Normal.

AORTA: Normal.

THORACIC SPINE: Normal.

OTHER VISUALIZED BONES: Normal. VISUALIZED SOFT TISSUES: Normal.

DIAPHRAGM: Normal.

VISUALIZED ABDOMEN: Normal. VISUALIZED NECK: Normal.

IMPRESSION:

No significant abnormality noted.

Recommend clinical correlation.

Dr. Monica Shekhawat MBBS, DNB

CONSULTANT RADIOLOGIST

Maria.

*****End Of Report*****